India's weight-loss drug market is poised for a significant transformation as several domestic manufacturers prepare to introduce generic versions of semaglutide, a popular GLP-1 therapy.
The patent for semaglutide is set to expire soon, allowing companies like Dr. Reddy’s Laboratories, Zydus Lifesciences, and Sun Pharmaceutical Industries to launch their products at reduced prices. This move is anticipated to cut costs by approximately 50%, making the treatment more accessible to a broader population.
Market Dynamics
Semaglutide, originally developed by Novo Nordisk for type-2 diabetes, has gained global popularity for its weight-loss benefits. The drug is marketed under various brand names, including Ozempic and Wegovy. With the impending launch of generics, analysts predict that prices could drop to between ₹3,000 and ₹4,000 per month, compared to the current ₹8,800 for Novo’s Ozempic.
The weight-loss drug market in India, which already exceeds ₹1,400 crore in sales, is projected to grow fivefold within five years, driven by the rising prevalence of obesity and diabetes in the country.
Competitive Landscape
Over 50 brands are expected to enter the market following the patent expiry, leading to fierce competition among pharmaceutical companies. The initial launches are anticipated from five to six companies between March 2026 and the first quarter of the next financial year.
Indian drugmakers are quickly adapting their marketing strategies to capture market share. For instance, Zydus is developing a user-friendly multi-use injection pen, while Mankind Pharma is establishing a dedicated obesity division.
Target Market and Accessibility
While the initial focus may be on higher-income segments, the potential market is vast, with an estimated 404 million Indians projected to be classified as overweight by 2030. This demographic shift underscores the importance of affordable treatment options.
Experts suggest that the influx of generics will not only benefit consumers but also expand the market to general practitioners, making treatments more accessible to price-sensitive patients.
Future Outlook
Despite the anticipated competition, innovator brands may retain a loyal customer base. Patients currently using branded drugs may prefer to continue with them due to established efficacy and brand recognition.
As the market evolves, companies will need to balance competitive pricing with quality to ensure patient trust and safety.
